Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 329993 in Subjects With Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs ISIS CRPRx (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Proof of concept
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Feb 2013 Top-line results are expected in mid-2013 according to an ISIS Pharmaceuticals media release.